

PRESS RELEASE

Date 2 February 2008
Contact Investor Relations: Fritz Hirsbrunner, Head of Finance & Corporate Services Division, Galenica Group
Media: Christina Hertig, Head of Corporate Communications, Galenica Group
Topic Injectafer[®] (Ferinject[®]): Recommendation of the FDA Advisory Committee

Injectafer[®] (Ferinject[®]): Recommendation of the FDA Advisory Committee:

Recommendation for approval when oral iron treatment is ineffective

The U.S. Food and Drug Administration's (FDA) Drug Safety and Risk Management Advisory Committee discussed yesterday, February 1, 2008, the new intravenous iron replacement therapy, Injectafer[®] (Ferinject[®], ferric carboxymaltose injection), for the treatment of iron deficiency anemia in women due to heavy uterine and postpartum bleeding. At the close of the meeting, the Advisory Committee voted that the available safety and efficacy data support a favorable risk / benefit profile of Injectafer[®] for the treatment of the mentioned patient groups in case of an unsatisfactory response to oral iron or an intolerance to oral iron.

Galenica and Luitpold Pharmaceuticals, Inc. are pleased with the recommendation for approval. The recommendation establishes a path forward with the FDA. Galenica and Luitpold are committed to working closely with the FDA to see the product through approval. The mentioned second line treatment recommendation, when oral iron is ineffective, is clearly in-line with the current labelling in Europe and in Switzerland: all countries have included a similar restriction, particularly due to the fact that all intravenous iron products are in the same situation.

The FDA is expected to make a decision on the New Drug Application (NDA) requesting approval for the use of Injectafer[®] in these patient populations by mid-March, 2008. The agency is not bound by the Committee's recommendation but takes its advice into consideration when reviewing products for approval.

The development program for Injectafer[®] represents the largest prospectively enrolled program of any intravenous iron product ever submitted to the Agency for approval. Data were derived from 12 studies involving more than 2,000 patients.

Iron deficiency anemia represents a significant health issue in women. More than half of the 4 million women in the United States who give birth each year develop iron deficiency and approximately 1 million of these women progress to iron deficiency anemia. In addition, as many as one in five women suffers from heavy uterine bleeding, defined as excessive or prolonged blood loss.

The innovative injectable iron replacement product Ferinject[®] was registered by the public health authorities in 18 EU countries in September 2007 and in Switzerland in November 2007. It has been used to treat iron deficiency diseases in Germany since November 2007 and will be on sale in Switzerland from mid-February 2008.

Galenica AG

P.O. Box · Untermattweg 8 · CH-3001 Berne
Tel. +41 58 852 85 17 · Fax +41 58 852 85 58
media@galenica.com · www.galenica.com

Date 2 February 2008
Page 2
Topic Injectafer® (Ferinject®): Recommendation of the FDA Advisory Committee

For further information please contact:

Galenica Group
Christina Hertig, Head of Communications
+41 (0)79 371 77 24

Galenica is a diversified group active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. The Galenica Group enjoys a leading position in all its business sectors – Pharma, Logistics, HealthCare Information and Retail. A large part of the Group's income is generated by international operations.

Additional information concerning the Galenica Group can be found on www.galenica.com.